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Surveillance of Viral Hepatitis – United States, 2013 
SUMMARY 
As part of the Centers for Disease Control and Prevention’s (CDC) National Notifiable Diseases 
Surveillance System (NNDSS), viral hepatitis case-reports are received electronically from state 
and territorial health departments via CDC’s National Electronic Telecommunications System 
for Surveillance (NETSS), a computerized public health surveillance system that provides CDC 
with data on cases of nationally notifiable diseases on a weekly basis. Although the surveillance 
infrastructure is in place for reporting of both acute and chronic infections, case-reports of 
chronic hepatitis B virus (HBV) and past or present hepatitis C virus (HCV) infections, which 
account for the greatest burden of disease, were submitted by 41 states and 37 states, 
respectively, in 2013. As noted in a report from the Institute of Medicine (1), surveillance 
capacity to monitor viral hepatitis is limited at the state and local level, resulting in under-
reporting and variable data quality. 
The NNDSS data in this report should be interpreted with the understanding that reported cases 
of viral hepatitis represent only those infected persons who were detected, diagnosed, met a 
stringent case definition, and eventually reported to CDC in 2013. Because many infections are 
not reported, this Summary is most useful in detecting trends over time in newly reported cases 
of hepatitis A virus (HAV), HBV, and HCV infections. In an effort to account for under-
ascertainment and under-reporting, a method was developed in 2011 to better quantify the 
number of new cases of hepatitis A, B, and C from the actual number cases reported for each 
disease (2). The estimates in this report were obtained using this new methodology. We caution 
the reader, however, that the estimates of the number of new cases after 2011, including those in 
this report, cannot be compared to estimates before 2011, which were obtained using a different 
(unpublished) methodology, but the trends seen in reported data still pertain, such as the increase 
in the number of acute cases of HCV infection among young persons that was observed 
beginning in 2011. 
Because chronic HBV and current HCV infections are largely hidden and part of what the former 
United States Assistant Secretary for Health, Dr. Howard Koh has dubbed the “Silent Epidemic” 
(3), this report also provides data to inform our understanding of the current epidemic of chronic 
hepatitis B and C. 
With progressive infant hepatitis A vaccination recommendations since 1996 and universal 
infant vaccination since 2006, vaccination rates and evidence of vaccine-induced immunity in 
young patients have been increasing in the past decade (4, 5). Despite protection among young 
persons, adults who do not fall into a high-risk group are not vaccinated and are therefore 
susceptible to infection. Since 2011, an increase in the number of reported cases of hepatitis A 
has been observed.  In 2013, there were 1,781 reported cases of hepatitis A, which represented a 
14% increase from 2012. This increase reflects cases ascertained during a large hepatitis A 
outbreak from imported pomegranate arils consumed by persons in several southwestern states 
and Hawaii (6). After adjusting for under-ascertainment and under-reporting (2), the estimated 
number of new HAV infections was 3,473. 
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Acute hepatitis B has been declining in incidence since 1990 mainly due to effective vaccination 
strategies, but for the first time since 1990, in 2013, the number of reported cases of acute 
hepatitis B increased to 3,050 cases, which represented a 5.4% increase from 2012. Although this 
increase may reflect the growing number of drug-related and healthcare-related outbreaks 
associated with hepatitis B transmission, it may be premature to interpret the increase from 2012-
2013; continued monitoring over more years of data is warranted. Chronic HBV infection, 
estimated at 700,000-1.4 million of the U.S. population (7, 8), remains a major public health 
challenge. As the surveillance data from enhanced surveillance sites in this report indicate, about 
one-half of chronic HBV infections were among Asians/Pacific Islanders, and 63.9% of chronic 
HBV infections were among persons born outside of the United States. Other data indicate that 
approximately 47%-70% of chronic HBV-infected persons living in the United States were born 
in other countries (9), and of foreign born persons living in the United States with chronic HBV 
infection, an estimated 58% migrated from Asia (8). Further, the mortality data in this report 
show that Asians/Pacific Islanders are disproportionately dying with hepatitis B. Identifying 
these chronically infected persons and linking them to care is critical (10, 11). In 2014, the U.S. 
Preventive Services Task Force (USPSTF) joined with CDC in recommending HBV testing for 
persons born in countries where  HBV infection is endemic (12). There were 3,050 cases of acute 
hepatitis B reported in 2013. After adjusting for under-ascertainment and  under-reporting (2), 
the estimated number of new HBV infections was 19,764. 
After receiving reports of approximately 800-1,000 cases of acute hepatitis C each year from 
2006-2010, there was a significant increase of 151.5% in reported cases of acute HCV infection 
from 2010 to 2013.  Cases of acute HCV infection rose from 850 in 2010 to 1,229 in 2011 to 
1,778 in 2012 and then to 2,138 in 2013. The increase from 2010-2013 is thought to reflect both 
true increases in incidence and improved case ascertainment. Based on these data and 
epidemiologic studies, new cases of HCV infection are predominately among young persons 
who are white, live in non-urban areas (particularly in Eastern and Midwestern states), have a 
history of injection drug use, and previously used opioid agonists such as oxycodone (13, 14). 
Improved ascertainment by Florida, Massachusetts, and New York, funded by CDC to conduct 
active surveillance, partially explains increased incidence in these sites.  In other locations where 
the number of cases has increased very markedly, such as Indiana, Kentucky, and New Jersey, 
the increases have occurred without any federal support for investigation or follow-up, reflecting 
overall increases in incidence (15) (Table 4.1). After adjusting for under-ascertainment and 
under-reporting (2), an estimated 29,718 new HCV infections occurred in 2013. 
Mortality among HCV-infected persons—primarily adults aged 55-64 years—is increasing (16, 
17). In  2007, the number of HCV-related deaths (n=15,106) exceeded the number of 
HIV/AIDS-related deaths (n=12,734) in the United States (16) and has since continued to 
increase. In 2013, the number of HCV-related deaths increased to 19,368; more than one-half of 
these deaths occurred among persons aged 55-64 years. A major public health challenge is to 
increase the proportion of persons tested and the proportion of those who test positive who are 
referred for care and treatment (10, 11). To address this challenge, in 2013, the USPSTF joined 
with CDC in recommending one-time screening for HCV infection to adults born between 1945 
and 1965 (18). 
  




Viral hepatitis is caused by infection with any of at least five distinct viruses: hepatitis A virus 
(HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis 
E virus (HEV). Most viral hepatitis infections in the United States are attributable to HAV, HBV, 
and HCV. All three of these unrelated viruses can produce an acute illness characterized by 
nausea, malaise, abdominal pain and jaundice, although many of these acute infections are 
asymptomatic or cause only mild disease. Thus, many persons infected with HBV or HCV are 
unaware they are infected and have clinically silent infections for decades until developing 
cirrhosis, end-stage liver disease, or hepatocellular carcinoma. 
Hepatitis A 
Transmitted through the fecal-oral route, HAV is acquired primarily through close personal 
contact with an infected person and during foodborne outbreaks (19). Unlike hepatitis B and C, 
hepatitis A does not cause chronic infection. Since 1995, effective vaccines to prevent HAV 
infection have been available in the United States, increasing the feasibility of eliminating 
indigenous transmission. In 1996, CDC’s Advisory Committee on Immunization Practices 
(ACIP) recommended administration of hepatitis A vaccine to persons at increased risk for the 
disease, including international travelers, men who have sex with men (MSM), non-injection and 
injection-drug users (IDUs), and children living in communities with high rates of disease (20). 
In 1999, ACIP expanded these recommendations to include children living in 11 states with 
average hepatitis A rates of >20 cases per 100,000 population and recommended that vaccination 
be considered for children in an additional six states with rates of 10–20 cases per 100,000 
population (21). ACIP expanded these recommendations in 2006 to include routine vaccination 
of newborns in all 50 states (4). 
Hepatitis B 
HBV is transmitted by percutaneous or mucosal exposure to the blood or body fluids of an 
infected person, from an infected mother to her newborn during childbirth, through close contact 
within households, through unscreened blood transfusion or unsafe injections in health care 
settings, through injection drug use, and from sexual contact with an infected person. Adults with 
diabetes mellitus are at an increased risk of acquiring HBV infection. Therefore, these persons 
are recommended to receive hepatitis B vaccination if younger than 60 years of age and to be 
considered for vaccination if aged 60 years or older (22). 
The risk for chronic HBV infection decreases with increasing age at infection. Of infants who 
acquired HBV infection from their mothers at birth, as many as 90% become chronically 
infected, whereas 30%–50% of children infected at age 1–5 years become chronically infected. 
This percentage is smaller among adults, in whom approximately 5% of all acute HBV infections 
progress to chronic infection (23, 24). 
Effective vaccines to prevent HBV infection have been available in the United States since 1981. 
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transmission in the United States (25, 26). This strategy encompassed the following four 
components: 
 Universal vaccination of infants beginning at birth; 
 Prevention of perinatal HBV infection through routine screening of all pregnant women 
for HBV infection and the provision of immunoprophylaxis to infants born either to 
infected women or to women of unknown infection status; 
 Routine vaccination of previously unvaccinated children and adolescents; and  
 Vaccination of adults at increased risk for infection (including health-care workers, 
dialysis patients, adults with diabetes, household contacts and sex partners of persons 
with chronic HBV infection, recipients of certain blood products, persons with a recent 
history of having multiple sex partners concurrently, those infected with a sexually 
transmitted disease, men who have sex with men [MSM], and injection drug users).  
In addition to hepatitis B vaccination, efforts have been made to improve care and treatment for 
persons who are living with hepatitis B. In the United States, 700,000-1.4 million persons are 
estimated to be infected with the virus (7, 27), many of whom are unaware of their infection 
status (10). To improve health outcomes for these persons, CDC issued recommendations in 
2008 to guide HBV testing and public health management of persons with chronic HBV 
infection (9). These guidelines stress the need for testing persons at high risk for infection, 
conducting contact management, educating patients, and administering FDA-approved therapies 
for treating hepatitis B. Other recent guidelines address the appropriate management of chronic 
HBV infection in surgeons, other health care workers, and students (28). 
Hepatitis C 
HCV is transmitted primarily through percutaneous (parenteral) exposure that can result from
injection drug use, needle stick injuries, and inadequate infection control in health-care settings. 
Much less often, HCV transmission occurs among HIV-positive persons, especially MSM, as a 
result of sexual contact with an HCV-infected partner (29, 30), among persons who receive 
tattoos in unregulated settings (30), and among infants born to HCV-infected mothers (31). After 
adjustment for non-sampled populations in NHANES, there are an estimated 3.2 million 
chronically HCV-infected persons in the United States (32). After adjustment for populations not 
sampled in the NHANES household surveys (32), such as the incarcerated and homeless, there 
are an estimated 3.2 million chronically HCV-infected persons in the United States (11). 
A single positive anti-HCV result cannot distinguish between acute and chronic HCV infection 
or between current or cleared HCV infection. Approximately 75%-85% of newly infected adults 
and adolescents develop chronic infection and making this distinction requires a health 
department to follow-up with a provider to determine if there were symptoms for reporting 
purposes. Laboratory criteria in the 2012 case definition for past or present HCV infection 
require one or more of the following: anti-HCV positive (repeatedly reactive) by EIA, verified 
by at least one more specific assay, or HCV RIBA positive, or HCV nucleic acid test (NAT) 
positive, or anti-HCV screening-test positive with an assay-specific signal-to-cutoff ratio 
predictive of a true case. In 2013, the RIBA test was phased out in the United States and the 
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of at least 4 records by hepatitis surveillance staff in health departments (34). No clinical 
symptoms are required; however, the case must be known to not be an acute case. 
Because of the high burden of current HCV infection in the United States and because no 
vaccine is available for preventing infection, national recommendations (35) emphasize other 
primary prevention activities, including screening and testing blood donors, inactivating HCV in 
plasma-derived products, testing persons at risk for HCV infection and providing them with risk-
reduction counseling, and consistently implementing and practicing infection control in health­
care settings. In 2010, the FDA approved point-of-care tests for HCV infection, which meant that 
patients could receive HCV test results within the same visit and faster referral to care (36). In 
2012, CDC augmented existing risk-based recommendations for HCV testing by recommending 
one-time screening for HCV infection among all those born during 1945-1965 (37). It is 
estimated that persons born during these years have a 3% prevalence of HCV antibodies, which 
is five times higher than the prevalence seen in adults born in other years. Of all persons living 
with HCV infection, about 75% were born during 1945-1965; a similar percentage of HCV-
associated deaths can be attributed to this birth cohort (37). The goal of birth-cohort HCV testing 
is to identify unrecognized infections among the segment of the population with the largest risk 
of HCV-associated morbidity and mortality, thereby increasing opportunities for persons 
infected with HCV to benefit from appropriate care and treatment.  
Linkage to care and treatment is critical to improving health outcomes for persons found to be 
infected with HCV. Such linkage is particularly important in light of the major advancements 
that have been made in HCV treatments. For patients infected with HCV, treatment has 
previously consisted of pegylated interferon combined with oral doses of ribavirin (38). 
Approximately 40%-50% of HCV-infected patients receiving this therapy cleared their infection 
(38). However, HCV treatment improved drastically in 2011 with the development of the initial 
direct-acting oral agents, telaprevir and boceprevir, which were capable of achieving a sustained 
virologic response rate of >80% (38, 39). These two drugs were available during the reporting 
period in 2013 that this Surveillance Report covers, but are now discontinued in the United 
States because of the development of newer all-oral direct-acting antiviral agents. In 2013, the 
FDA approved the use of simeprevir and sofosbuvir (40). When given in combination with 
pegylated interferon and ribavirin or together as an all-oral combination regimen for a shorter 
duration of 8-12 weeks, these agents  increase virologic cure rates to >90% (41, 42). In 2014, 
two new all-oral regimens, Harvoni (ledipasvir/sofosbuvir) and Viekira Pak (ombitasvir, 
paritaprevir, and ritonavir tablets; dasabuvir tablets), were licensed for the treatment of HCV.
These four agents are now the standard-of-care for HCV treatment in the United States.  
Evidence-based guidance is available from AASLD/IDSA to assist providers caring for HCV-
infected patients (43). The AASLD/IDSA HCV guidance is continuously updated to incorporate 
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Sources of Information 
CDC relies on several sources of information to determine the incidence, prevalence, trends, and 
burden of hepatitis A, B, and C disease.  
National Notifiable Diseases Surveillance System (NNDSS) 
Background 
The basis for most case-reports is passive surveillance through the National Notifiable Diseases 
Surveillance System (NNDSS). State and local health departments report acute hepatitis A, B and 
C (incident cases) through this system. However, a number of states do not report cases of 
chronic hepatitis B and C through the NNDSS. Collecting, verifying and reporting the many 
chronic cases of hepatitis B and C in the United States (estimated at over 4 million) are beyond 
the capability of many health departments. Reports of chronic hepatitis B and C are included in 
this Surveillance Summary from NNDSS from states that gave permission for CDC to publish 
those counts.  
Each week, state and territorial health departments report cases of acute, symptomatic viral 
hepatitis to CDC’s NNDSS. Since 1990, states have been electronically submitting individual 
case-reports (absent of personal identifiers) to CDC. States’ participation in reporting nationally 
notifiable diseases, including viral hepatitis, is voluntary.  
National surveillance for viral hepatitis (including acute hepatitis A, hepatitis B, and hepatitis C; 
chronic hepatitis B; and chronic [past or present] hepatitis C) is based on case definitions 
developed and approved by the Council of State and Territorial Epidemiologists (CSTE) and 
CDC. Reported cases of acute and chronic viral hepatitis are required to meet the following 
clinical and laboratory criteria (available at: 
http://wwwn.cdc.gov/nndss/script/ConditionList.aspx?Type=0&Yr=2012).  However, these 
criteria are evaluated at state or local health departments and are not validated by CDC. Although 
states may classify cases as confirmed, probable, and suspect, only confirmed cases of acute viral 
hepatitis are presented in this report. 
Adjustments to Reported Cases from the National Notifiable Diseases Surveillance System 
To better estimate the incidence of acute hepatitis A, B, and C in the United States, CDC recently 
undertook an analysis to recalculate the multipliers that had been used previously to account for 
under-ascertainment and under-reporting. A model was developed and tested that factored in the 
probability of symptoms (I), referral to care and treatment (II), and rates of reporting to local and 
state health departments (III). Results of the analysis indicated that reported cases represent an 
estimated one of every 1.95 hepatitis A cases, one of every 6.48 acute hepatitis B cases, and one 
of every 13.90 acute hepatitis C cases (2). Accordingly, to obtain the estimated number of acute 
hepatitis A, B, and C after accounting for under-ascertainment and  under-reporting, these new 
estimators were first applied to the acute hepatitis case data from NNDSS in the 2011 
Division of Viral Hepatitis, CDC 
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Surveillance Summary and will continue to be applied to future annual surveillance summaries, 
including in this report. These estimates cannot be used to deduce trends by comparison with 
estimations obtained in years prior to 2011, as earlier estimates were based on different (and 
unpublished) calculations; still, trends in reported cases can be evaluated, for example, the trend 
in the increase in acute hepatitis C that was first observed in 2011 among nationally reported 
cases. 
Enhanced Viral Hepatitis Surveillance Sites 
Background  
In November 2012, CDC funded seven health departments to conduct enhanced viral hepatitis 
surveillance through a three-year CDC funding agreement.  All chronic cases of viral hepatitis 
obtained through these sites are de-duplicated. Additionally, for a sample of cases and in some 
sites such as New York State, all cases, follow-up case investigation is conducted by health 
departments to obtain clinical, laboratory, and epidemiological information, including risk 
behaviors and exposures. Each quarter, a dataset of cumulative cases from each site was sent to 
CDC through the CDC Secure Access Management System, a secure electronic file transfer 
portal.  
Methods 
In 2013, CDC funded four states (Florida, Massachusetts, Michigan, and Washington), two cities 
(Philadelphia and San Francisco), and 57 counties in New York State to conduct ‘enhanced’ – 
that is, active – viral hepatitis surveillance, representing a combined population of approximately 
35.6 million persons. In each of these jurisdictions, clinical laboratories were mandated to submit 
laboratory reports from persons with positive HBV and HCV test results to state or local health 
departments. Participating health departments routinely review each report to assess whether the 
current case definitions were met as established by CSTE and CDC. To determine whether a case 
is new, each site matches new case-reports to existing cases in the surveillance registry using 
personal identifying information. New cases are added to an electronic registry, whereas 
duplicate cases are used to update previous reports. Most health departments collect basic 
demographic data (e.g., age and sex) from the laboratory reports. Efforts vary by site regarding 
the level of investigation undertaken to collect and store supplemental information (e.g., risk 
factor data) from patients or their providers. 
Data analyses from participating enhanced surveillance sites presented in this surveillance report 
were conducted on all serologically-confirmed cases of chronic hepatitis B and chronic (past or 
present) hepatitis C infection reported for the year 2013. Rates were calculated using appropriate 
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The number of cases of chronic HBV infection and past or present HCV infection from 
participating enhanced surveillance sites included in this report is likely an underestimate of the 
true burden of disease because cases of chronic infection are generally asymptomatic and less 
likely to be identified and reported. Additionally, data from these sites are not representative of 
the U.S. population, and because not all sites conduct comprehensive follow-up, data regarding 
race/ethnicity, place of birth, and risk are missing for some case-reports.  
Mortality/Death Certificates 
Background 
Death certificates are completed for all deaths registered in the United States. Information from 
death certificates is provided by funeral directors, attending physicians, medical examiners, and 
coroners, and certificates are filed in vital statistics offices within each state and the District of 
Columbia. Through a program called the National Vital Statistics System (NVSS) (44), 
information from death certificates is compiled by CDC’s National Center for Health Statistics 
(NCHS) to produce national multiple-cause-of-death (MCOD) data (44); causes of death are 
coded in accordance with the International Classification of Diseases, Tenth Revision (ICD-10) 
(45). MCOD data are used to determine the national burden of mortality associated with viral 
hepatitis and to characterize decedents. 
A major study of these records from 1999-2007 showed that the annual number of deaths among 
HCV-infected persons exceeded the annual number of deaths among HIV-infected persons since 
2007 (16). Another study showed that fewer than 20% of HCV-infected decedents have HCV 
listed on their death certificate, even though 75% or more had pre-mortem evidence of serious 
liver disease  (17). 
Methods 
We obtained and analyzed 2009-2013 national multiple-cause mortality data through NVSS. The 
following case definitions were used to identify a death associated with hepatitis A, B, and C. 
Any death record with a report of any of the following ICD-10 codes listed as the underlying or 
one of the multiple (e.g., contributing) causes of death in the record axis: 
 Hepatitis A (ICD-10: B15), 
 Hepatitis B (ICD-10: B16, B17.0, B18.0, and B18.1), or 
 Hepatitis C (ICD-10: B17.1 and B18.2). 
Demographic information on age, race/ethnicity, and sex were examined. Deaths were divided 
into six age categories: 0–34, 35–44, 45–54, 55–64, 65–74, and >75 years. Race categories prior 
to 2010 consisted of white (Hispanic and non-Hispanic), black (Hispanic and non-Hispanic), and 
non-black, non-white (which included all other racial and ethnic groups). Beginning in 2010, 
race/ethnicity was examined and consisted of the following categories: White, non-Hispanic, 
Black, non-Hispanic, Hispanic, Asian/Pacific Islander (API) and American Indian/Alaska Native 
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(AI/AN) to be consistent with those used by the Division of Viral Hepatitis (DVH). To calculate 
national mortality rates, the number of deaths associated with each type of hepatitis was divided 
by the total U.S. Census population for each demographic characteristic. Rates on race/ethnicity, 
sex, and overall total were standardized to the age distribution of the U.S. standard population in 
2000 (46).  
 
Interpretation of Mortality Data 
 Differences in recording practices of death certificate information may cause 
misclassification of ICD-10 codes and demographic information. 
 Certain racial/ethnic populations likely are underrepresented in US Census data (the 
denominator for calculating rates), potentially causing overestimated rates for these 
populations. 
 Analyses do not adjust for deaths resulting from undiagnosed viral hepatitis infections.  
 Death records listing more than one type of viral hepatitis infection were counted once 
for each type of infection. For example, a death with ICD-10 codes for both hepatitis B 
and C virus infections is counted once as a hepatitis B death and once as a hepatitis C 
death. 
 Before 2010, the race category designated as “non-white/non-black” included all other 
racial groups (e.g., APIs, AI/ANs, and persons who are Hispanic). This lack of specificity 
limits race-specific interpretation of mortality data prior to 2010. 
Investigation of Healthcare-Associated Outbreak Cases 
In 2013, CDC participated in two state-based investigations of healthcare-associated outbreaks of 
viral hepatitis infection, one involving HBV infection and one involving HCV infection. 
Additional information may be found at the following link that summarizes known outbreaks 
that occurred during 2008-2014 (available at: 
http://www.cdc.gov/hepatitis/Statistics/HealthcareOutbreakTable.htm).  
  




Hepatitis A  
Historically, hepatitis A rates vary cyclically, with nationwide increases every 10-15 years. The 
last peak was in 1995; since that time, rates of hepatitis A generally declined until 2011. In 2013, 
a total of 1,781 cases of hepatitis A were reported from 50 states to CDC (Table 2.1), a 14% 
increase from 2012. This reflects cases ascertained during a large hepatitis A outbreak from 
imported pomegranate arils consumed by persons in several southwestern states and Hawaii (6). 
The overall incidence rate in 2013 was 0.6 cases per 100,000 population. After adjusting for 
under-ascertainment and under-reporting, an estimated 3,473 hepatitis A cases occurred in 2013. 
(Data for 2013 were unavailable for the District of Columbia.) 
 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms (e.g., fever, 
headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain) and 2) jaundice, 
or elevated serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels. 
Laboratory Criteria  
Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive. 
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Table 2.1. Reported cases of hepatitis A, nationally and by state ― United States, 2009-
2013 
State 
2009 2010 2011 2012 2013 
Rate* (No.) Rate (No.) Rate (No.) Rate (No.) Rate (No.) 
Alabama 0.3 (12) 0.2 (8) 0.2 (8) 0.4 (19) 0.2 (10) 
Alaska 0.3 (2) 0.7 (5) 0.6 (4) 0.1 (1) 0.1 (1) 
Arizona 1.0 (68) 1.0 (61) 1.2 (77) 1.4 (93) 1.0 (66) 
Arkansas 0.4 (12) 0.1 (2) 0.1 (3) 0.3 (8) 0.3 (9) 
California 0.7 (273) 0.6 (242) 0.5 (186) 0.5 (209) 0.7 (255) 
Colorado 1.0 (52) 0.7 (36) 0.4 (21) 0.5 (28) 1.0 (51) 
Connecticut 0.5 (18) 0.8 (29) 0.5 (18) 0.6 (23) 0.5 (19) 
Delaware 0.5 (4) 0.8 (7) 0.2 (2) 1.0 (9) 0.4 (4) 
District of 
Columbia 0.2 (1) 0.2 (1) U U U U U U 
Florida 0.9 (171) 0.7 (139) 0.5 (87) 0.5 (87) 0.6 (115) 
Georgia 0.5 (54) 0.4 (40) 0.3 (27) 0.5 (46) 0.4 (36) 
Hawaii 0.8 (11) 0.6 (8) 0.6 (8) 0.4 (5) 1.1 (16) 
Idaho 0.3 (5) 0.5 (8) 0.4 (6) 0.7 (11) 0.5 (8) 
Illinois 1.0 (126) 0.4 (48) 0.6 (73) 0.5 (67) 0.6 (79) 
Indiana 0.3 (17) 0.2 (12) 0.4 (24) 0.2 (11) 0.5 (32) 
Iowa 1.3 (38) 0.4 (11) 0.3 (8) 0.2 (7) 0.6 (17) 
Kansas 0.4 (12) 0.5 (14) 0.1 (4) 0.5 (15) 0.4 (11) 
Kentucky 0.3 (12) 0.6 (26) 0.2 (10) 0.6 (25) 0.5 (24) 
Louisiana 0.1 (6) 0.2 (11) 0.1 (5) 0.2 (7) 0.3 (14) 
Maine 0.1 (1) 0.5 (7) 0.5 (6) 0.7 (9) 0.8 (10) 
Maryland 0.8 (47) 0.4 (23) 0.4 (26) 0.5 (28) 0.5 (29) 
Massachusetts 1.1 (71) 0.7 (48) 0.6 (39) 0.6 (40) 0.6 (43) 
Michigan 0.7 (72) 0.7 (73) 0.7 (70) 1.0 (100) 0.8 (83) 
Minnesota 0.6 (29) 0.7 (37) 0.5 (27) 0.5 (29) 0.6 (32) 
Mississippi 0.3 (9) 0.1 (2) 0.2 (7) 0.4 (11) 0.2 (5) 
Missouri 0.4 (21) 0.4 (21) 0.2 (13) 0.3 (20) 0.1 (8) 
Montana 0.6 (6) 0.4 (4) 0.3 (3) 0.6 (6) 0.6 (6) 
Nebraska 1.2 (21) 0.8 (14) 0.3 (5) 0.9 (16) 0.7 (13) 
Nevada 0.6 (15) 0.5 (14) 0.2 (5) 0.4 (10) 0.7 (19) 
New Hampshire 0.5 (7) 0.2 (2) 0.0 (0) 0.5 (6) 0.7 (9) 
New Jersey 0.8 (71) 0.9 (76) 0.9 (79) 0.7 (60) 0.8 (68) 
New Mexico 0.4 (8) 0.2 (5) 0.3 (7) 0.5 (10) 1.0 (20) 
New York 0.7 (136) 0.8 (147) 0.6 (113) 0.6 (111) 0.8 (167) 
North Carolina 0.4 (41) 0.5 (48) 0.3 (31) 0.3 (34) 0.5 (46) 
North Dakota 0.3 (2) 0.6 (4) 0.0 (0) 0.3 (2) 1.2 (9) 
Ohio 0.3 (36) 0.4 (47) 0.3 (39) 0.3 (36) 0.5 (59) 
Oklahoma 0.2 (7) 0.2 (6) 0.3 (11) 0.3 (12) 0.4 (14) 
Oregon 0.5 (19) 0.4 (17) 0.3 (11) 0.2 (9) 0.7 (29) 
Pennsylvania 0.5 (68) 0.4 (53) 0.5 (60) 0.5 (62) 0.4 (53) 
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Rhode Island 0.9 (9) 0.9 (9) 0.8 (8) 0.3 (3) 0.4 (4) 
South Carolina 1.4 (63) 0.6 (26) 0.2 (11) 0.1 (6) 0.3 (14) 
South Dakota 0.4 (3) 0.1 (1) 0.2 (2) 0.0 (0) 0.5 (4) 
Tennessee 0.2 (13) 0.2 (12) 0.4 (23) 0.4 (23) 0.3 (20) 
Texas 0.7 (184) 0.6 (139) 0.5 (138) 0.5 (134) 0.4 (109) 
Utah 0.3 (7) 0.4 (12) 0.3 (8) 0.1 (4) 0.4 (12) 
Vermont 0.3 (2) 0.0 (0) 1.0 (6) 0.3 (2) 1.1 (7) 
Virginia 0.5 (42) 0.6 (52) 0.4 (30) 0.6 (49) 0.4 (36) 
Washington 0.6 (42) 0.3 (21) 0.5 (31) 0.4 (29) 0.6 (45) 
West Virginia 0.3 (6) 0.8 (15) 0.4 (8) 0.4 (8) 0.2 (4) 
Wisconsin 0.6 (33) 0.4 (23) 0.1 (8) 0.4 (21) 0.6 (37) 
Wyoming 0.4 (2) 0.7 (4) 0.4 (2) 0.2 (1) 0.0 (0) 
Total 0.6 (1,987) 0.5 (1,670) 0.4 (1,398) 0.5 (1,562) 0.6 (1,781) 
 
*Rate per 100,000 population.  
U=No data available for reporting. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of hepatitis A cases reported in the United States has declined, from 1,987 
reported cases in 2009 to 1,781 reported cases in 2013.  
 However, the 1,781 hepatitis A cases in 2013 represent an increase of 14% from 1,562 
cases in 2012 due to a large outbreak in 2013 (6).  
 Of the 50 states that reported hepatitis A cases in 2013, 27 states had rates below the 
national rate.  
 In 2013, the case rate ranged from no cases in Wyoming to 1.2 cases per 100,000 
population in North Dakota.  
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Table 2.2. Clinical characteristics of reported cases of hepatitis A ― United States, 2013 
Clinical characteristic 
Availability of 






No. % No. % 
Jaundice 1,095 61.5 753 68.8 
Hospitalized for hepatitis A 1,081 60.7 519 48.0 
Died from hepatitis A 959 53.8 9 0.9 
*A total of 1,781 hepatitis A cases were reported during 2013. 
†Case-reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with 
any other response were excluded. 
§Numbers and percentages represent only those case-reports for which data regarding clinical characteristics were 
available; numbers likely are underestimates. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Of the 1,781 case-reports of hepatitis A received during 2013, 61.5% included 
information about whether the patient had jaundice, 60.7% included information 
regarding hospitalization caused by hepatitis A, and 53.8% included information on death 
from hepatitis A. 
 Jaundice was reported for 753 (68.8%) of the 1,095 hepatitis A case-reports that included 
information about jaundice. 
 Hospitalization as the result of hepatitis A was reported for 519 (48.0%) of the 1,081 
hepatitis A case-reports that included information about hospitalization. 
 Death from hepatitis A was reported for 9 (0.9%) of the 959 hepatitis A case-reports that 
included information about death.  
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of hepatitis A cases declined by 86.7%, from 13,397 in 2000 to 1,781 in 
2013. 
 The number of hepatitis A cases increased by 27.4% from 1,398 in 2011 to 1,781 2013 

























































Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2000-2011, rates of hepatitis A declined among all age groups but only continued 
to decline in 2012 and 2013 among cases aged 0-9 and 10-19 years.  
 When comparing the 2013 hepatitis A rates of all age groups, persons aged 30–39 years 
had the highest rate (0.74 cases per 100,000 population) and persons aged 0-9 years had 
the lowest rate (0.14 cases per 100,000 population). 
 The largest increases were among persons aged 30-39 years (from 0.51 cases per 100,000 
population in 2011 to 0.74 cases per 100,000 population in 2013) and persons aged 40–49 
years (from 0.39 cases per 100,000 population in 2011 to 0.64 cases per 100,000 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2000-2011, rates of hepatitis A among males and females both declined, and by 
2011, the rates in these two groups were similar.  
 Rates among males and females have increased proportionally from 2011-2013. 
 In 2013, the incidence rate was 0.6 cases per 100,000 population for males and females. 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2000-2007, rates of hepatitis A among Hispanics were generally higher than those 
of other racial/ethnic populations.  
 Since 2008, the rate of hepatitis A has been higher for Asians/Pacific Islanders (0.57 
cases per 100,000 population in 2013) than for other race/ethnic groups. 
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Figure 2.5. Availability of information on risk exposures/behaviors associated with 











*Includes case-reports indicating the presence of at least one of the following risks 2–6 weeks prior to onset of 
acute, symptomatic hepatitis A: 1)  having traveled to hepatitis A-endemic regions of Mexico, South/Central 
America,  Africa,  Asia/South Pacific, or the Middle East; 2) having sexual/household or other contact with 
suspected/confirmed hepatitis A patient; 3) being a child/employee in day care center/nursery/preschool  or having 
had contact with such persons; 4) being involved in a foodborne/waterborne outbreak; 5) being a man who has sex 
with men; and 6) using injection drugs. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Of the 1,781 case-reports of hepatitis A received by CDC during 2013, a total of 718 
(40%) cases did not include a response (i.e., a “yes” or “no” response to any of the 
questions about risk exposures and behaviors) to enable assessment of risk exposures or 
behaviors. 
 Of the 1,063 case-reports that had risk exposure/behavior information: 
o 803 (75.5%) indicated no risk exposures/behaviors for hepatitis A; and  
o 260 (24.5%) indicated at least one risk exposures/behaviors for hepatitis A during 
the 2–6 weeks prior to onset of illness.  
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Figure 2.6a. Hepatitis A reports*, by risk exposure/behavior† – United States, 2013 
 
*A total of 1,781 case-reports of hepatitis A were received in 2013. 
†More than one risk exposure/behavior may be indicated on each case-report. 
§No risk data reported. 
¶A total of 864 hepatitis A cases were reported among males in 2013. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
Figure 2.6a presents reported risk exposures/behaviors for hepatitis A during the incubation 
period, 2–6 weeks prior to onset of symptoms: 
 Of the 771 case-reports that included information about travel, 6.2% (n= 48) indicated 
traveling outside of the United States or Canada.  
 Of the 628 case-reports that included information about injection-drug use, 4.0% (n=25) 
indicated use of injection drugs. 
 Of the 73 case-reports from males that included information about sexual 
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*A total of 1,781 case-reports with hepatitis A were received in 2013.
†More than one risk exposure/behavior may be indicated on each case-report.
§No risk data reported.
Source: CDC, National Notifiable Diseases Surveillance System.
Figure 2.6b presents reported risk exposures/behaviors during the incubation period, 2–6 weeks 
prior to onset of symptoms: 
 Of the 744 case-reports that contained information about contact with a hepatitis A-
infected person, 5.6% (n=42) indicated sexual or household contact with a person
confirmed or suspected of having hepatitis A.
 Of the 881 case-reports that included information about employment or attendance at a
nursery, daycare center, or preschool, 3.4% (n=30) indicated working at or attending a
nursery, day-care center, or preschool.
 Of the 779 case-reports that included information about household contact with an
employee of or a child attending a nursery, day-care center, or preschool, 6.2% (n=48)
indicated such contact.
 Of the 734 case-reports that included information about linkage to an outbreak, 12.8%
(n=94) indicated exposure that may have been linked to a common-source foodborne or
waterborne outbreak.
 Of the 744 case-reports that included information about additional contact (i.e., other than
household or sexual contact) with someone confirmed or suspected of having hepatitis A,
1.6% (n=12) indicated such contact.
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Table 2.3. Number and rate of hepatitis A-related deaths, by demographic characteristics 
and year — United States, 2009–2013 
Demographic characteristic 
2009 2010 2011 2012 2013 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years) 
0–34 1 0.00 3 0.00 0 0.00 2 0.00 2 0.00 
35–44 1 0.00 7 0.02 1 0.00 5 0.01 2 0.00 
45–54 14 0.03 25 0.06 11 0.02 12 0.03 13 0.03 
55–64 22 0.06 34 0.09 16 0.04 23 0.06 30 0.08 
65–74 12 0.06 10 0.05 12 0.05 17 0.07 19 0.08 
>75 32 0.17 16 0.09 29 0.15 18 0.09 14 0.07 
Race§ 
White 68 0.02 







65 0.03 44 0.02 51 0.02 63 0.02 
Black, NH 15 0.04 10 0.03 8 0.02 6 0.01 
Hispanic 12 0.03 6 0.02 8 0.02 8 0.02 
Asian/Pacific 
Islander 




1 0.05 1 0.04 2 0.08 0 0.00 
Sex 
Male 50 0.03 73 0.05 37 0.02 46 0.03 50 0.03 
Female 32 0.02 22 0.01 32 0.02 31 0.02 30 0.01 
Overall 82 0.02 95 0.03 69 0.02 77 0.02 80 0.02 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on
the International Classification of Diseases, 10th Revision (ICD-10) codes B15 (hepatitis A).
§The race category "White" Included white, non-Hispanic and white Hispanic. The race category "Black" included
black, non-Hispanic and black Hispanic. The race category "Non-White, non-Black" included all other races.
¶The race/ethnicity category was added starting in 2010 to incorporate bridged race categories. One death in 2012 is
not represented under the race/ethnicity category due to missing race and/or ethnicity data.
Source: CDC, National Vital Statistics System.
 In 2013, the overall hepatitis A-related mortality rate was 0.02 deaths per 100,000
population (n=80).
 From 2009-2013, the hepatitis A-related mortality rate remained steady at 0.02
deaths/100,000 population each year, except in 2010 when the mortality rate was 0.03
deaths/100,000 population.
 In 2013, hepatitis A-related mortality rates were higher among persons aged ≥45 years
(>0.03 deaths/100,000 population) when compared to persons aged 0-44 years (0.00
deaths/100,000 population).
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 In 2013, hepatitis A-related age-specific mortality rates increased with increasing age 
groups from 0.00 deaths/100,000 population among persons aged 0-34 years to 0.08 
deaths/100,000 population among persons aged 55-64 years and 65-74 years to 0.07 
deaths/100,000 population among persons aged >75 years.  
 In 2013, the persons with the highest hepatitis A-related mortality rates were aged 55-64 
and 65-74 years (0.08 deaths/100,000 population for each age group). 
 In 2013, hepatitis A-related mortality rates were higher in males, 0.03 deaths/100,000 
population, than in females, 0.01 deaths/100,000 population.  




Acute Hepatitis B  
In 2013, a total of 3,050 cases of acute hepatitis B were reported from 48 states to CDC (Table 
3.1). The overall incidence rate for 2013 was 1.0 case per 100,000 population. After adjusting for 
under-ascertainment and under-reporting, an estimated 19,764 acute hepatitis B cases occurred in 
2013. (Data for 2013 were unavailable for the District of Columbia, Rhode Island, and 
Wyoming.) 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Acute hepatitis is defined as acute illness with 1) discrete onset of symptoms* (e.g., fever, 
headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain) and 2) jaundice or 
elevated serum alanine aminotransferase (ALT) >100 IU/L. 
Laboratory Criteria  
 Hepatitis B surface antigen (HBsAg) positive  
  AND  
 Immunoglobulin M (IgM) antibody to hepatitis B core antigen (IgM anti-HBc) 
positive (if done) 
 
*A documented negative HBsAg laboratory test result within 6 months prior to a 
positive test (either HBsAg, hepatitis B "e" antigen (HBeAg), or hepatitis B virus nucleic 
acid testing (HBV NAT) including genotype) result does not require an acute clinical 
presentation to meet the surveillance case definition. 
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Table 3.1. Reported cases of acute hepatitis B, nationally and by state ― United States, 
2009-2013 
State 
2009 2010 2011 2012 2013 
Rate* (No.) Rate (No.) Rate (No.) Rate (No.) Rate (No.) 
Alabama 1.9 (89) 1.4 (68) 2.5 (119) 1.6 (79) 1.9 (90) 
Alaska 0.6 (4) 0.7 (5) 0.4 (3) 0.1 (1) 0.1 (1) 
Arizona 0.6 (42) 0.4 (26) 0.2 (14) 0.2 (14) 0.4 (28) 
Arkansas 2.2 (65) 2.3 (66) 1.9 (57) 2.5 (74) 1.7 (50) 
California 0.7 (258) 0.7 (252) 0.4 (157) 0.4 (136) 0.4 (138) 
Colorado 0.5 (27) 0.9 (46) 0.4 (23) 0.5 (24) 0.5 (24) 
Connecticut 0.5 (16) 0.6 (22) 0.5 (19) 0.4 (15) 0.2 (8) 
Delaware† U U U U 1.4 (13) 1.2 (11) 1.5 (14) 
District of 
Columbia 1.7 (10) 0.5 (3) U U U U U U 
Florida 1.6 (299) 1.6 (297) 1.1 (213) 1.3 (247) 1.7 (323) 
Georgia 1.5 (144) 1.7 (165) 1.4 (142) 1.1 (109) 1.0 (104) 
Hawaii 0.5 (6) 0.4 (6) 0.4 (6) 0.4 (5) 0.3 (4) 
Idaho 0.7 (11) 0.4 (6) 0.1 (2) 0.3 (5) 0.8 (13) 
Illinois 0.9 (118) 1.1 (135) 0.7 (85) 0.7 (86) 0.7 (94) 
Indiana 1.2 (74) 1.2 (75) 1.1 (70) 1.4 (90) 1.5 (101) 
Iowa 1.2 (37) 0.5 (15) 0.5 (15) 0.4 (13) 0.4 (11) 
Kansas 0.2 (6) 0.4 (11) 0.5 (15) 0.3 (9) 0.4 (11) 
Kentucky 2.1 (90) 3.1 (136) 3.5 (151) 4.1 (180) 4.9 (214) 
Louisiana 1.6 (73) 1.2 (55) 1.4 (62) 1.0 (44) 1.8 (82) 
Maine 1.1 (15) 1.0 (13) 0.6 (8) 0.7 (9) 0.8 (11) 
Maryland 1.3 (72) 1.2 (67) 1.1 (62) 0.9 (52) 0.7 (43) 
Massachusetts 0.3 (17) 0.2 (13) 1.0 (67) 1.1 (75) 1.1 (71) 
Michigan 1.3 (132) 1.2 (122) 0.9 (91) 0.8 (81) 0.5 (53) 
Minnesota 0.7 (38) 0.4 (23) 0.4 (20) 0.3 (17) 0.4 (19) 
Mississippi 1.1 (33) 1.1 (33) 1.9 (57) 2.6 (78) 1.8 (55) 
Missouri 0.8 (47) 1.1 (67) 1.0 (60) 0.8 (48) 1.0 (61) 
Montana 0.1 (1) 0.0 (0) 0.0 (0) 0.2 (2) 0.4 (4) 
Nebraska 1.2 (22) 0.7 (12) 0.7 (12) 0.5 (10) 0.5 (9) 
Nevada 1.3 (34) 1.5 (41) 1.1 (29) 1.0 (28) 1.0 (29) 
New Hampshire 0.5 (6) 0.4 (5) 0.2 (3) 0.3 (4) 0.2 (2) 
New Jersey 1.1 (93) 0.9 (77) 0.8 (73) 0.8 (70) 0.7 (65) 
New Mexico 0.4 (8) 0.2 (5) 0.5 (10) 0.1 (3) 0.1 (3) 
New York 0.7 (129) 0.7 (139) 0.7 (134) 0.6 (113) 0.6 (117) 
North Carolina 1.1 (104) 1.2 (113) 1.1 (109) 0.7 (73) 0.8 (75) 
North Dakota 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0) 
Ohio 0.8 (88) 0.8 (95) 0.8 (90) 1.5 (178) 1.9 (225) 
Oklahoma 3.3 (122) 3.1 (115) 2.6 (100) 2.1 (79) 1.0 (40) 
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Oregon 1.2 (44) 1.1 (42) 0.8 (32) 0.6 (25) 0.8 (32) 
Pennsylvania 0.8 (106) 0.6 (72) 0.7 (84) 0.5 (63) 0.3 (43) 
Rhode Island U U U U U U U U U U 
South Carolina 1.2 (56) 1.3 (59) 0.8 (39) 0.8 (37) 1.2 (58) 
South Dakota 0.5 (4) 0.2 (2) 0.2 (2) 0.2 (2) 0.6 (5) 
Tennessee 2.2 (136) 2.4 (150) 3.0 (192) 3.7 (240) 4.0 (262) 
Texas 1.7 (420) 1.6 (394) 0.8 (204) 0.7 (170) 0.5 (142) 
Utah 0.2 (5) 0.3 (8) 0.4 (10) 0.5 (13) 0.2 (5) 
Vermont 0.0 (0) 0.3 (2) 0.0 (0) 0.3 (2) 0.3 (2) 
Virginia 1.4 (110) 1.2 (97) 1.0 (84) 1.0 (84) 0.9 (72) 
Washington 0.7 (48) 0.7 (50) 0.5 (35) 0.5 (34) 0.5 (33) 
West Virginia 4.6 (84) 4.7 (88) 6.1 (113) 7.6 (141) 10.5 (195) 
Wisconsin 0.4 (24) 0.9 (54) 0.3 (17) 0.4 (22) 0.2 (9) 
Wyoming 0.7 (4) 0.5 (3) 0.0 (0) 0.0 (0) U U 
Total 1.1 (3,371) 1.1 (3,350) 0.9 (2,903) 0.9 (2,895) 1.0 (3,050) 
*Rate per 100,000 population.  
†Updated data for Delaware in 2011.  
U=No data available for reporting. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of acute cases of hepatitis B decreased by 9.5% during 2009–2013, from 
3,371 reported cases to 3,050 reported cases; increases in Florida, Indiana, Kentucky, 
Massachusetts, Mississippi, Missouri, Ohio, Tennessee and West Virginia occurred 
during this time period. 
 Of the 48 states that reported acute hepatitis B cases in 2013, 31 states had rates below 
the national rate of 1.0 per 100,000 population.  
 Rates of acute hepatitis B in 2013 ranged from no cases reported in North Dakota to 10.5 
cases per 100,000 population in West Virginia. 
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No. % No. % 
Jaundice 2,149 70.5 1,653 76.9 
Hospitalized for hepatitis B 2,125 69.7 1,250 58.8 
Died from hepatitis B 2,018 66.2 18 0.9 
 
*A total of 3,050 hepatitis B cases were reported during 2013. 
†Case-reports for which questions regarding clinical characteristics were answered with “yes” or “no.” Reports with 
any other response were excluded. 
§Numbers and percentages represent only those case-reports for which data regarding clinical characteristics were 
available; numbers likely are underestimates. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 
 Of the 3,050 case-reports of acute hepatitis B received in 2013, 70.5% included 
information regarding whether the patient had jaundice, 69.7% included information 
regarding hospitalization caused by hepatitis B, and 66.2% included information on death 
from hepatitis B. (Note: more severe cases are likely to be ascertained and reported.) 
 Jaundice was reported for 1,653 (76.9%) of the 2,149 acute hepatitis B case-reports that 
included information about jaundice. 
 Hospitalization as the result of hepatitis B was reported for 1,250 (58.8%) of the 2,125 
acute hepatitis B case-reports that included information about hospitalization. 
 Death from hepatitis B was reported for 18 (0.9%) of the 2,018 acute hepatitis B case-
reports that included information about death.  
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Figure 3.1. Reported number of acute hepatitis B cases — United States, 2000-2013 
 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of reported cases of acute hepatitis B decreased by 62%, from 8,036 in 2000 
to 3,050 in 2013. 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2003-2011, rates of acute hepatitis B declined among all age groups.  
 From 2011-2013, rates of acute hepatitis B increased among the 30-39 and 40-49 year 
age groups but remained steady among the other age groups. 
 In 2013, rates were highest for persons aged 30–39 years (2.42 cases/100,000 
population); the lowest rates were among children and adolescents aged <19 years (0.03 
cases/100,000 population). 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 While the incidence rate of acute hepatitis B remained higher for males than for females, 
the gap narrowed from 2002-2013.  
 Incidence rates of acute hepatitis B decreased for both males and females from 2000-
2012, but slightly increased from 2012-2013 for both. 
 In 2013, the rate for males was approximately 1.7 times higher than that for females (1.21 
cases and 0.73 cases per 100,000 population, respectively). 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2000-2013, the rate of acute hepatitis B declined among all racial/ethnic 
populations, except for a 58.3% increase among American Indians/Alaska Natives from 
2001-2002 and a 10.8% increase among non-Hispanic Whites from 2012-2013.   
 In 2013, the rate of acute hepatitis B was lowest among Asians/Pacific Islanders (0.33 
cases per 100,000 population) and highest for non-Hispanic Blacks (0.95 cases per 
100,000 population). 
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Figure 3.5. Availability of information on risk exposures/behaviors associated with acute 











* Includes case-reports indicating the presence of at least one of the following risks 6 weeks to 6 months prior to 
onset of acute, symptomatic hepatitis B:  1) using injection drugs; 2) having sexual contact with 
suspected/confirmed hepatitis B patient; 3) being a man who has sex with men; 4) having multiple sex partners 
concurrently; 5) having household contact with suspected/confirmed hepatitis B patient; 6) occupational exposure to 
blood; 7) being a hemodialysis patient; 8) having received a blood transfusion; 9) having sustained a percutaneous 
injury; and 10) having undergone surgery. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Of the 3,050 case-reports of acute hepatitis B received by CDC during 2013, a total of 
1,214 (40%) did not include a response (i.e., a “yes” or “no” response to any of the 
questions about risk exposures and behaviors) to enable assessment of risk exposures or 
behaviors.  
 Of the 1,836 case-reports that had risk exposure/behavior information:  
o 1,149 (62.6%) indicated no risk exposure/behavior for acute hepatitis B. 
o 687 (37.4%) indicated at least one risk exposure/behavior for acute hepatitis B 
during the 6 weeks to 6 months prior to illness onset. 
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*A total of 3,050 case-reports of acute hepatitis B were received in 2013. 
† More than one risk exposure/behavior may be indicated on each case-report. 
§ No risk data reported. 
¶A total of 1,873 acute hepatitis B cases were reported among males in 2013. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
Figure 3.6a presents reported risk exposures/behaviors for hepatitis B during the incubation 
period, 6 weeks to 6 months prior to onset of symptoms.  
 Of the 1,428 case-reports that included information about injection-drug use, 23.2% 
(n=332) indicated use of injection drugs. 
 Of the 965 case-reports that included information about sexual contact, 5.0% (n=48) 
indicated sexual contact with a person with confirmed or suspected hepatitis B. 
 Of the 167 case-reports from males that included information about sexual 
preference/practices, 26.9% (n=45) indicated sex with another man.  
 Of the 665 case-reports that had information about number of sex partners, 26.2% 
(n=174) indicated having ≥2 sex partners. 
 Of the 965 case-reports that included information about household contact, 0.7% (n=7) 
indicated household contact with someone with confirmed or suspected hepatitis B. 
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*A total of 3,050 case-reports of hepatitis B were received in 2013. 
†More than one risk exposure/behavior may be indicated on each case-report. 
§Risk data not reported. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
Figure 3.6b presents reported risk exposures/behaviors during the incubation period, 6 weeks to 
6 months prior to onset of symptoms.  
 Of the 1,577 case-reports that included information about occupational exposures, 0.1% 
(n=1) indicated employment in a medical, dental, or other field involving contact with 
human blood. 
 Of the 1,217 case-reports that included information about receipt of dialysis or kidney 
transplant, 0.1% (n=1) indicated patient receipt of dialysis or a kidney transplant. 
 Of the 1,493 case-reports that included information about receipt of blood transfusion, 
0.7% (n=11) indicated patient receipt of a blood transfusion. 
 Of the 1,482 case-reports that included information about surgery, 9.9% (n=147) 
indicated having surgery. 
 Of the 1,358 case-reports that included information about needle stick injury, 4.5% 
(n=61) indicated having an accidental needle stick/puncture. 
Surveillance for Viral Hepatitis — United States, 2013 
36 
 
Chronic Hepatitis B  
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
No symptoms are required. Persons with chronic HBV infection may have no evidence of liver 
disease or may have a spectrum of disease ranging from chronic liver disease to cirrhosis or liver 
cancer.  
Laboratory Criteria  
 IgM antibodies to IgM anti-HBc negative AND a positive result on one of the following 
tests: HBsAg, HBeAg, or nucleic acid test for hepatitis B virus DNA (including 
qualitative, quantitative and genotype testing), OR 
 HBsAg positive or nucleic acid test for HBV DNA positive (including qualitative, 
quantitative and genotype testing) or HBeAg positive two times at least 6 months apart 
(Any combination of these tests performed 6 months apart is acceptable.) 
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hepatitis B  
case-reports 
submitted Data source 
Colorado¶ 511 NNDSS 
Delaware 126 State-provided 
Florida¶ 4,270 NNDSS 
Iowa 266 State-provided 
Kansas 108 State-provided 
Maine¶ 107 State-provided 
Michigan¶ 1,130 State-provided 
Minnesota¶ 189 NNDSS 
Montana¶ 21 State-provided 
New Jersey** 303 NNDSS 
New Mexico¶ 119 NNDSS 
New York (minus New York City)** 636 State-provided 
New York City** 5,857 State-provided 
Oregon** 150 State-provided 
Pennsylvania¶ 1,512 State-provided 
South Carolina†† 448 NNDSS 
South Dakota¶ 79 NNDSS 
West Virginia¶ 212 State-provided 
Total 16,044   
 
Abbreviation: NNDSS, National Notifiable Diseases Surveillance System 
* For case-definition, see http://wwwn.cdc.gov/nndss/script/ConditionList.aspx?Type=0&Yr=2012 
†Reports may not reflect unique cases. 
§Jurisdictions that gave permission to report their number of chronic HBV cases 
¶Includes confirmed and probable case-reports only. 
**Includes confirmed case-reports only. 




 In 2013, 41 states reported 31,763 case-reports of chronic hepatitis B. 
 Eighteen states agreed to publication of their chronic hepatitis B case data for this report, 
representing 50.5% (n=16,044) of all reports of chronic hepatitis B received by CDC in 
2013.  
 Of the 18 states, the greatest number of reports was from New York City (n=5,857); the 
least number of reports was from Montana (n=21). 
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Table 3.4. Reported cases of chronic hepatitis B, by demographic characteristics and 
laboratory tests – Enhanced Viral Hepatitis Surveillance Sites, 2013 
Category 
MA MI NYS Phil SF WA§ Total 
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Sex               
 Female 
224 207 236 118 339 72 1,196 
49.1% 43.9% 36.5% 42.1% 46.3% 42.4% 43.4% 
 Male 
231 264 409 162 387 91 1,544 
50.7% 56.1% 63.2% 57.9% 52.9% 53.5% 56.0% 
  Unknown/missing 
1 0 2 0 6 7 16 
0.2% 0.0% 0.3% 0.0% 0.8% 4.1% 0.6% 
Race/ethnicity                
 American 
Indian/Alaskan Native,  
non-Hispanic (NH) 
0 5 1 0 0 4 10 
0.0% 1.1% 0.2% 0.0% 0.0% 2.4% 0.4% 
 Asian/Pacific Islander,  
NH 
177 114 176 98 364 48 977 
38.8% 24.2% 27.2% 35.0% 49.7% 28.2% 35.4% 
 Black,  NH 
80 98 83 52 9 5 327 
17.5% 20.8% 12.8% 18.6% 1.2% 2.9% 11.9% 
 White,  NH 
46 124 99 14 16 30 329 
10.1% 26.3% 15.3% 5.0% 2.2% 17.6% 11.9% 
 Hispanic 
30 7 29 12 0 5 83 
6.6% 1.5% 4.5% 4.3% 0.0% 2.9% 3.0% 
 Other,  NH 
29 26 26 9 6 5 101 
6.4% 5.5% 4.0% 3.2% 0.8% 2.9% 3.7% 
 Unknown/missing 
94 97 233 95 337 73 929 
20.6% 20.6% 36.0% 33.9% 46.0% 42.9% 33.7% 
Age group, years               
 0-14  
7 9 5 3 6 4 34 
1.5% 1.9% 0.8% 1.1% 0.8% 2.4% 1.2% 
 15-24 
34 31 60 22 49 15 211 
7.5% 6.6% 9.3% 7.9% 6.7% 8.8% 7.7% 
 25-39 
165 143 240 93 258 48 947 
36.2% 30.4% 37.1% 33.2% 35.2% 28.2% 34.4% 
 40-54 
141 147 189 101 215 62 855 
30.9% 31.2% 29.2% 36.1% 29.4% 36.5% 31.0% 
 55+ 
109 141 153 61 204 41 709 
23.9% 29.9% 23.6% 21.8% 27.9% 24.1% 25.7% 
 Unknown/missing 
0 0 0 0 0 0 0 
0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
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Place of birth 
 United States 
39 127 12 139 10 U 327 
8.6% 27.0% 1.9% 49.6% 1.4% 12.6% 
 Outside United States 
224 121 47 120 67 U 579 
49.1% 25.7% 7.3% 42.9% 9.2% 22.4% 
 Unknown/missing 
193 223 588 21 655 U 1,680 
42.3% 47.3% 90.9% 7.5% 89.5% 65.0% 
Hepatitis B laboratory 
testing¶ 
 HBV surface antigen + 
399 269 541 233 654 81 2,177 
87.5% 57.1% 83.6% 83.2% 89.3% 47.6% 79.0% 
 [IgM anti-HBc] - 
77 25 106 0 0 42 250 
16.9% 5.3% 16.4% 0.0% 0.0% 24.7% 9.1% 
 HBV "e" antigen + 
155 2 99 64 75 12 407 
34.0% 0.4% 15.3% 22.9% 10.2% 7.1% 14.8% 
 HBV NAT + 
281 4 203 228 465 45 1,226 
61.6% 0.8% 31.4% 81.4% 63.5% 26.5% 44.5% 
Total no. cases  456 471 647 280 732 170 2,756 
2013 Estimated 
population total** 
6,692,824 9,895,622 11,245,290 1,553,165 837,442 5,405,750 35,630,093 
Rate per 100,000 
population 
6.8 4.8 5.8 18.0 87.4 3.1 7.7 
Abbreviations: MA, Massachusetts; MI, Michigan; NYS, New York State; Phil, Philadelphia; SF, San Francisco; 
WA, Washington State 
*Chronic hepatitis B data from Florida, one of the 7 funded sites, were not included in this table.  Chronic hepatitis 
B data from all funded sites, including Florida, will be published in an updated table in July.
†Cases and population estimates from New York excluded those who resided in New York City.
§Cases from Washington excluded Snohomish County, Pierce County, and 90% of King County.
¶Cases can be reported with more than one laboratory test result. The denominator used to calculate proportions was 
the total number of cases reported for each site.
**Population estimates for the United States: https://wonder.cdc.gov/bridged-race-population.html. Population 
estimates from Washington excluded Snohomish and Pierce Counties.
U = No data available for reporting.
Source: CDC, Enhanced Viral Hepatitis Surveillance Sites.
 In 2013, a total of 2,756 chronic hepatitis B cases were reported by six funded sites.
 San Francisco reported the greatest number of cases (n=732, 26.6%) and highest rate
(87.4 cases/100,000 population) of chronic hepatitis B compared with the other sites.
 Among the 2,740 cases for which sex was known, 56.4% were male. By site, the
proportion of cases that were male ranged from 50.8% in Massachusetts to 63.4% in New
York State.
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 Among the 1,827 cases for which race/ethnicity was known, 53.5% were non-Hispanic 
Asians/Pacific Islanders. By site, the proportion of non-Hispanic Asians/Pacific Islanders 
ranged from 30.5% in Michigan to 92.2% in San Francisco. 
 Most (n=1,802; 65.4%) cases of chronic hepatitis B were among persons aged 25–54 
years.  
 Among the 906 cases for which place of birth was known, those born outside of the 
United States accounted for the greatest number of chronic hepatitis B cases (n=579, 
63.9%). By site, the proportion of reported chronic hepatitis B cases born outside of the 
United States ranged from 46.3% in Philadelphia to 87.0% in San Francisco. 
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Table 3.5. Number and rate of hepatitis B-related deaths, by demographic characteristics 
and year – United States, 2009-2013 
Demographic characteristic 
2009 2010 2011 2012 2013 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years) 
0–34 39 0.03 48 0.03 41 0.03 38 0.03 40 0.03 
35–44 143 0.34 142 0.35 143 0.35 123 0.30 146 0.36 
45–54 469 1.05 448 1.00 421 0.94 428 0.97 389 0.89 
55–64 547 1.57 610 1.67 645 1.69 639 1.66 704 1.79 
65–74 254 1.22 296 1.36 285 1.27 314 1.31 343 1.36 
>75 245 1.30 248 1.34 269 1.42 229 1.20 251 1.29 
Race§ 
White 978 0.35         
Black 320 0.87         
Non-White, 
non-Black 






  856 0.34 832 0.32 818 0.31 868 0.33 
Black, NH   356 0.94 373 0.98 322 0.81 384 0.98 
Hispanic   136 0.43 161 0.48 139 0.39 149 0.39 
Asian/Pacific 
Islander 




  17 0.73 9 0.38 18 0.74 14 0.55 
Sex 
Male 1,267 0.80 1,316 0.81 1,321 0.80 1,272 0.75 1,375 0.79 
Female 430 0.24 476 0.27 483 0.26 499 0.27 498 0.26 
Overall 1,697 0.51 1,792 0.52 1,804 0.52 1,771 0.50 1,873 0.52 
 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000. 
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on 
the International Classification of Diseases, 10th Revision (ICD-10) codes B16, B17.0, B18.0, B18.1 (hepatitis B). 
§The race category "White" Included white, non-Hispanic and white Hispanic. The race category "Black" included 
black, non-Hispanic and black Hispanic. The race category "Non-White, non-Black" included all other races. 
¶The race/ethnicity category was added starting in 2010 to incorporate bridged race categories. Six deaths in 2010, 
seven deaths in 2011, five deaths in 2012, and seven deaths in 2013 are not represented under the race/ethnicity 
category due to missing race and/or ethnicity data. 
Source: CDC, National Vital Statistics System. 
 
 
 In 2013, the hepatitis B-related mortality rate was 0.5 deaths/100,000 population 
(n=1,873). 
 From 2009-2013, the hepatitis B-related mortality rate remained steady at 0.5 
deaths/100,000 population. 
 In 2013, Asians/Pacific Islanders had the highest hepatitis B-related mortality rate of 2.6 
deaths/100,000 population compared to other racial/ethnic groups. Persons aged 55–64 
years had the highest age-specific mortality rate, 1.8 deaths/100,000 population. 
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 In 2013, males who died with hepatitis B had a mortality rate that was nearly three times 
the mortality rate of females who died with hepatitis B (0.8 deaths/100,000 population vs. 
0.3 deaths/100,000 population). From 2009-2013, the hepatitis B-related mortality rate 
remained relatively stable for males and females. 
  




Acute Hepatitis C 
In 2013, a total of 2,138 cases of acute hepatitis C were reported from 41 states to CDC (Table 
4.1). The overall incidence rate for 2013 was 0.7 cases per 100,000 population, an increase from 
2009-2012. After adjusting under-ascertainment and under-reporting, an estimated 29,718 acute 
hepatitis C cases occurred in 2013. (Data for 2013 were unavailable for Alaska, Arizona, 
Connecticut, the District of Columbia, Hawaii, Iowa, Mississippi, New Hampshire, Rhode 
Island, and Wyoming.)  
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
An acute illness with a discrete onset of any sign or symptom* consistent with acute viral 
hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal 




One or more of the following three criteria:  
 Antibodies to hepatitis C virus (anti-HCV) screening-test-positive with a signal-to-cutoff 
ratio predictive of a true positive as determined for the particular assay as defined by 
CDC. (URL for the signal to cut-off ratios: 
http://www.cdc.gov/hepatitis/HCV/LabTesting.htm), OR 
 Hepatitis C Virus Recombinant Immunoblot Assay (HCV RIBA) positive, OR 
 Nucleic Acid Test (NAT) for HCV RNA positive (including qualitative, quantitative or 
genotype testing)  
 
AND, if done meets the following two criteria:  
 Absence of IgM antibody to hepatitis A virus (if done) (IgM anti-HAV), AND 
 Absence of IgM anti-HBc (if done)  
*A documented negative HCV antibody laboratory test result followed within 6 months by a 
positive test (as described in the laboratory criteria for diagnosis) result does not require an acute 
clinical presentation to meet the surveillance case definition. 
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Table 4.1. Reported cases of acute hepatitis C, nationally and by state ― United States, 
2009-2013 
State 
2009 2010 2011 2012 2013 
Rate* (No.) Rate (No.) Rate (No.) Rate (No.) Rate (No.) 
Alabama 0.2 (10) 0.1 (7) 0.5 (23) 0.5 (24) 0.6 (30) 
Alaska U U U U U U U U U U 
Arizona U U U U U U U U U U 
Arkansas 0.1 (2) 0.0 (1) 0.0 (0) 0.2 (5) 1.0 (30) 
California 0.1 (43) 0.1 (32) 0.1 (48) 0.2 (63) 0.2 (72) 
Colorado 0.6 (28) 0.4 (20) 0.5 (28) 0.8 (42) 0.4 (21) 
Connecticut 1.5 (53) 1.0 (37) 1.3 (47) 0.9 (34) U U 
Delaware U U U U 0.3 (3) U U 0.0 (0) 
District of 
Columbia 0.2 (1) 0.3 (2) U U U U U U 
Florida 0.3 (53) 0.3 (56) 0.3 (64) 0.6 (107) 0.7 (134) 
Georgia 0.3 (31) 0.3 (32) 0.5 (53) 0.8 (82) 0.5 (48) 
Hawaii U U U U U U U U U U 
Idaho 0.5 (7) 0.7 (11) 0.8 (12) 0.7 (11) 0.9 (14) 
Illinois 0.0 (6) 0.0 (1) 0.0 (6) 0.2 (26) 0.3 (37) 
Indiana 0.3 (22) 0.4 (27) 1.3 (84) 1.7 (110) 2.7 (175) 
Iowa 0.4 (11) 0.0 (0) 0.0 (0) 0.1 (3) U U 
Kansas 0.0 (1) 0.1 (2) 0.3 (8) 0.6 (16) 0.6 (17) 
Kentucky 1.5 (64) 2.5 (109) 3.2 (142) 4.1 (178) 5.1 (226) 
Louisiana 0.2 (9) 0.1 (4) 0.2 (7) 0.2 (11) 0.4 (19) 
Maine 0.2 (2) 0.2 (2) 0.9 (12) 0.6 (8) 0.6 (8) 
Maryland 0.4 (23) 0.4 (24) 0.6 (35) 0.7 (39) 0.9 (53) 
Massachusetts 0.2 (10) 0.2 (13) 0.3 (23) 0.6 (37) 2.6 (174) 
Michigan 0.4 (35) 0.5 (45) 0.3 (32) 0.8 (76) 0.7 (74) 
Minnesota 0.3 (15) 0.3 (16) 0.3 (17) 0.6 (32) 0.9 (47) 
Mississippi U U U U U U U U U U 
Missouri 0.0 (0) 0.1 (6) 0.1 (8) 0.1 (4) 0.1 (6) 
Montana 0.1 (1) 0.4 (4) 0.9 (9) 0.9 (9) 1.6 (16) 
Nebraska 0.2 (3) 0.1 (2) 0.1 (2) 0.2 (3) 0.1 (2) 
Nevada 0.2 (5) 0.3 (7) 0.4 (10) 0.4 (12) 0.3 (9) 
New Hampshire U U U U U U U U U U 
New Jersey 0.1 (7) 0.3 (28) 0.6 (53) 0.8 (71) 1.2 (106) 
New Mexico 0.3 (6) 0.7 (14) 0.7 (14) 1.0 (21) 0.6 (12) 
New York 0.3 (53) 0.3 (50) 0.3 (52) 0.5 (93) 0.7 (131) 
North Carolina 0.3 (24) 0.4 (39) 0.6 (60) 0.6 (63) 0.8 (79) 
North Dakota 0.3 (2) 0.0 (0) 0.0 (0) 0.0 (0) 0.6 (4) 
Ohio 0.2 (26) 0.1 (10) 0.1 (6) 0.1 (7) 1.0 (116) 
Oklahoma 0.7 (27) 1.1 (41) 1.4 (53) 2.1 (80) 1.0 (40) 
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Oregon 0.5 (19) 0.5 (19) 0.5 (20) 0.9 (37) 0.4 (14) 
Pennsylvania 0.3 (39) 0.2 (26) 0.3 (35) 0.5 (66) 0.6 (81) 
Rhode Island U U U U U U U U U U 
South Carolina 0.0 (1) 0.0 (1) 0.0 (1) 0.0 (1) 0.0 (0) 
South Dakota U U U U U U U U 0.0 (1) 
Tennessee 0.5 (33) 0.7 (46) 1.3 (83) 2.0 (129) 1.5 (98) 
Texas 0.1 (36) 0.1 (35) 0.1 (37) 0.2 (44) 0.1 (28) 
Utah 0.2 (6) 0.4 (10) 0.4 (10) 0.6 (17) 0.4 (11) 
Vermont 0.2 (1) 0.3 (2) 1.0 (6) 1.0 (6) 0.5 (3) 
Virginia 0.1 (10) 0.2 (13) 0.3 (25) 0.9 (76) 0.5 (41) 
Washington 0.3 (22) 0.4 (25) 0.6 (41) 0.8 (54) 0.9 (63) 
West Virginia 1.7 (31) 1.1 (21) 2.5 (46) 3.0 (55) 3.1 (58) 
Wisconsin 0.1 (3) 0.2 (10) 0.3 (15) 0.5 (26) 0.7 (40) 
Wyoming 0.0 (0) 0.0 (0) 0.4 (2) U U U U 
Total 0.3 (781) 0.3 (850) 0.4 (1,232) 0.6 (1,778) 0.7 (2,138) 
*Rate per 100,000 population.
U=No data available for reporting.
Source: CDC, National Notifiable Diseases Surveillance System.
 The number of acute cases of hepatitis C reported in the United States increased each
year from 2009-2013.
 The number of acute cases of hepatitis C reported in the United States increased 20%,
from 1,778 reported cases in 2012 to 2,138 reported cases in 2013.
 The national rate of acute cases of hepatitis C remained stable, at 0.3 cases per 100,000
population from 2008 through 2010, but increased to 0.4 cases per 100,000 population in
2011, to 0.6 cases per 100,000 population in 2012, and to 0.7 cases per 100,000
population in 2013.
 Of the 41 states that submitted reports of acute hepatitis C in 2013, 22 states had rates
below the national rate of 0.7 cases per 100,000 population.
 Rates of acute hepatitis C ranged from no cases reported in Delaware and South Carolina
to 5.1 cases per 100,000 population reported in Kentucky.
 Twelve of 41 reporting states – California, Florida, Indiana, Kentucky, Massachusetts,
Michigan, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Tennessee –
accounted for 68.6% of acute cases reported in 2013.
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No. % No. % 
Jaundice 1,491 69.7 963 64.6 
Hospitalized for hepatitis C 1,382 64.6 794 57.5 
Died from hepatitis C 1,291 60.4 3 0.2 
 
*A total of 2,138 hepatitis C cases were reported during 2013. 
†Case-reports for which questions regarding clinical characteristics were answered with “yes” or “no.” 
Reports with any other response were excluded. 
§Numbers and percentages represent only those case-reports for which data regarding clinical 
characteristics were available; numbers likely are underestimates. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 
 Of the 2,138 case-reports of acute hepatitis C received during 2013, 69.7% (n = 1,491) 
included information about whether the patient had jaundice, 64.6% (n = 1,382) included 
information regarding hospitalization caused by hepatitis C, and 60.4% (n = 1,291) 
included information on death from hepatitis C. (Note: more severe cases are likely to be 
ascertained and reported.) 
 Jaundice was reported for 963 (64.6%) of the 1,491 acute hepatitis C case-reports that 
included information about jaundice. 
 Hospitalization as the result of hepatitis C was reported for 794 (57.5%) of the 1,382 
acute hepatitis C case-reports that included information about hospitalization. 
 Death from hepatitis C was reported for 3 (0.2%) of the 1,291 acute hepatitis C case-
reports that included information about death.  
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 The number of reported cases of acute hepatitis C declined until 2003 and remained 
steady until 2010.  However, from 2010-2013, there was an approximate 2.5-fold 
increase in the number of reported acute hepatitis C cases from 850 to 2,138 cases.   
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Figure 4.2. Incidence of acute hepatitis C, by age group — United States, 2000-2013 
 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 From 2000-2002, incidence rates for acute hepatitis C decreased among all age groups, 
except for persons aged 0–19 years; rates remained fairly constant among all age groups 
from 2002-2010. 
 In 2013, the rate of acute hepatitis C increased among all age groups, except for persons 
aged 0-19 years and ≥60 years, compared with rates in 2010. The largest increases were 
among persons aged 20–29 years (from 0.75 cases per 100,000 population in 2010 to 
2.01 cases per 100,000 population in 2013) and persons aged 30-39 years (from 0.60 
cases per 100,000 population in 2010 to 1.36 cases per 100,000 population in 2013).   
 In 2013, among all age groups, persons aged 20–29 years had the highest rate (2.01 cases 
per 100,000 population) and persons aged ≥60 years had the lowest rate (0.10 cases per 
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Figure 4.3. Incidence of acute hepatitis C, by sex — United States, 2000-2013 
 
  
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Incidence rates of acute hepatitis C decreased among males and females from 2000-2003 
and remained fairly constant from 2004-2010. 
 From 2010-2013, rates of acute hepatitis C increased among males and females; in 2013, 
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Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Rates for acute hepatitis C decreased among all racial/ethnic populations from 2000-
2003. 
 From 2002-2013, the incidence rate of acute hepatitis C remained higher for American 
Indians/Alaska Natives relative to other racial/ethnic groups. Incidence rates have since 
increased for all racial/ethnic populations. 
 From 2011-2012, acute hepatitis C rates increased by 86.2% among American 
Indians/Alaska Natives, 100% among Asian and Pacific Islanders, 7.1% among non-
Hispanic Blacks, 36.2% among non-Hispanic Whites, and 23.5% among Hispanics.  
 From 2012-2013, acute hepatitis C rates decreased 14.3% among American 
Indians/Alaska Natives and 20% among Asian and Pacific Islanders. Rates increased for 
non-Hispanic Blacks (33.3%), non-Hispanic Whites (28.1%), and Hispanics (4.8%).  
 In 2013, rates of acute hepatitis C among American Indians/Alaska Natives; 
Asians/Pacific Islanders; Black, non-Hispanic; White, non-Hispanic; and Hispanics were 
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Figure 4.5. Availability of information on risk exposures/behaviors associated with acute 











*Includes case-reports indicating the presence of at least one of the following risks 2 weeks to 6 months prior to 
onset of acute, symptomatic hepatitis C:  1) using injection drugs; 2) having sexual contact with 
suspected/confirmed hepatitis C patient; 3) being a man who has sex with men; 4) having multiple sex partners 
concurrently; 5) having household contact with suspected/confirmed hepatitis C patient; 6) having had occupational 
exposure to blood; 7) being a hemodialysis patient; 8) having received a blood transfusion; 9)  having sustained a 
percutaneous injury; and 10) having undergone surgery. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
 Of the 2,138 case-reports of acute hepatitis C received by CDC during 2013, 899 (42.0%) 
did not include a response (i.e., a “yes” or “no” response to any of the questions about 
risk exposures and behaviors) to enable assessment of risk exposures or behaviors. 
 Of 1,239 case-reports that had risk exposure/behavior information: 
o 454 (36.6%) indicated no risk exposure/behavior for hepatitis C. 
o 785 (63.4%) indicated at least one risk exposure/behavior in the 2 weeks to 6 
months prior to illness onset. 
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*A total of 2,138 case-reports of acute hepatitis C were received in 2013.   
† More than one risk exposure/behavior may be indicated on each case-report. 
§Risk data not reported.  
¶A total of 1,142 acute hepatitis C cases were reported among males in 2013. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
Figure 4.6a presents reported risk exposures/behaviors for hepatitis C during the incubation 
period, 2 weeks to 6 months prior to onset of symptoms. 
 Of the 955 case-reports that had information about injection drug use, 61.6% (n=588) 
indicated use of injection drugs. 
 Of the 183 case-reports from males that included information about sexual 
preferences/practices, 16.4% (n=30) indicated sex with another man.  
 Of the 76 case-reports that had information about sexual contact, 18.4% (n=14) reported 
sexual contact with a person with confirmed or suspected hepatitis C. 
 Of the 616 case-reports that had information about number of sex partners, 31.3% 
(n=193) indicated having ≥2 sex partners. 
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*A total of 2,137 case-reports of acute hepatitis C were received in 2013. 
†More than one risk exposure/behavior may be indicated on each case-report. 
§Risk data not reported. 
Source: CDC, National Notifiable Diseases Surveillance System. 
 
Figure 4.6b presents reported risk exposures/behaviors during the incubation period, 2 weeks to 
6 months prior to onset of symptoms. 
 Of the 887 case-reports that included information about occupational exposures, 1.0% 
(n=9) indicated employment in a medical, dental, or other field involving contact with 
human blood. 
 Of the 811 case-reports that included information about receipt of dialysis or a kidney 
transplant, 0.2% (n=2) indicated patient receipt of dialysis or a kidney transplant. 
 Of the 729 case-reports that included information about surgery, 12.2% (n=89) indicated 
having surgery. 
 Of the 679 case-reports that included information about needle sticks, 7.7% (n=52) 
indicated having an accidental needle stick/puncture. 
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Hepatitis C, Past or Present 
2012 CSTE/CDC Case Definition (NNDSS) 
Clinical Description 
Most persons infected with HCV are asymptomatic; however, many have chronic liver disease, 
which can range from mild to severe. 
Laboratory Criteria 
One or more of the following three criteria (except in persons less than 18 months of age, for 
whom only criteria 3 would meet the case classification criteria):  
 Anti-HCV screening-test positive with a signal-to-cutoff ratio predictive of a true positive 
as determined for the particular assay as defined by CDC. (URL for the signal-to-cutoff 
ratios: http://www.cdc.gov/hepatitis/HCV/LabTesting.htm), OR 
 HCV RIBA positive, OR 
 NAT for HCV RNA positive (including qualitative, quantitative or genotype testing). 
  
Division of Viral Hepatitis, CDC 
55 







submitted Data source 
Colorado 2,982 State-provided 
Connecticut¶ 2,749 State-provided 
Florida¶ 19,759 NNDSS 
Kansas 1,532 State-provided 
Maine** 1,265 State-provided 
Michigan¶ 6,719 State-provided 
Minnesota** 1,601 NNDSS 
Montana¶ 1,141 State-provided 
New Jersey** 6,580 NNDSS 
New Mexico 959 State-provided 
New York (minus New York City)** 6,633 State-provided 
New York City** 6,822 State-provided 
Oregon** 3,772 State-provided 
Pennsylvania¶ 8,882 State-provided 
South Carolina†† 3,238 NNDSS 
South Dakota** 405 NNDSS 
West Virginia** 4,503 State-provided 
Total 79,542 
Abbreviation: NNDSS, National Notifiable Diseases Surveillance System 
* For case-definition, see http://wwwn.cdc.gov/nndss/script/ConditionList.aspx?Type=0&Yr=2012.
†Reports may not reflect unique cases.
§Jurisdictions that gave permission to report their number of chronic HBV cases
¶Includes confirmed and probable case-reports only.
**Includes confirmed case-reports only.
††Includes confirmed, probable, and suspect case-reports.
 In 2013, 37 states reported 132,452 case-reports of chronic hepatitis C (past or present).
 Seventeen states agreed to publication of their past/present hepatitis C case data for this
report, representing 60.0% (n=79,542) of all reports of past/present hepatitis C received
by CDC in 2013.
 Of the 17 states, the greatest number of reports was received from Florida (n=19,759); the
least number of reports was received from South Dakota (n=405).
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Table 4.4. Reported cases of past or present hepatitis C, by demographic characteristics 
and laboratory tests – Enhanced Viral Hepatitis Surveillance Sites, 2013 
Category 
MA MI NYS Phil SF WA§ Total 
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 




























































































































































































































































 Anti-HCV+ 4,145 2,367 5,165 890 896 1,640 15,103 
80.5% 38.3% 77.9% 69.9% 69.9% 60.1%  65.0% 
 HCV RNA + 3,820 1,402 5,575 1,120 780 1,476 14,173 
74.2% 22.7% 84.0% 88.0% 60.8% 54.1% 61.0% 
Total no. cases  5,146 6,181 6,633 1,273 1,282 2,729 23,244 
2013 Estimated 
population total** 
6,692,824 9,895,622 11,245,290 1,553,165 837,442 5,405,750 35,630,093 
Rate per 100,000 
population 
76.9 62.5 59.0 82.0 153.1 50.5 65.2 
Abbreviations: MA, Massachusetts; MI, Michigan; NYS, New York State; Phil, Philadelphia; SF, San Francisco; 
WA, Washington State 
*Past or present hepatitis C data from Florida, one of the 7 funded sites, were not included in this table.  Past or
present hepatitis C data from all funded sites, including Florida, will be published in an updated table in July.
†Cases and population estimates from New York excluded those who resided in New York City.
§Cases from Washington excluded Snohomish County, Pierce County, and 90% of King County.
¶Cases can be reported with more than one laboratory test result. The denominator used to calculate proportions was
the total number of cases reported for each site.
**Population estimates for the United States: https://wonder.cdc.gov/bridged-race-population.html. Population
estimates from Washington excluded Snohomish and Pierce Counties.
Source: CDC, Enhanced Viral Hepatitis Surveillance Sites.
 In 2013, a total of 23,244 past or present hepatitis C cases were reported by six funded
sites.
 New York state reported more cases of past or present hepatitis C (n=6,633, 28.5%)
compared with the other sites. However, San Francisco had the highest rate of past or
present hepatitis C with 153.1 cases per 100,000 population reported.
 Among the 23,086 cases for which sex was known, most (62.8%) were male. By site, the
proportion of male cases ranged from 57.8% in Washington to 69.3% in San Francisco.
 Among the 14,240 cases for which race/ethnicity was known, non-Hispanic Whites
accounted for the greatest proportion (67.8%) of past or present hepatitis C. By site, the
proportion of non-Hispanic Whites ranged from 32.4% in Philadelphia to 76.3% in
Massachusetts.
 Among the 23,222 cases for which age was known, 63.5% were among persons aged >40
years.
 65.0% of cases had a positive hepatitis C virus antibody test result reported. The
proportion with a positive hepatitis C virus antibody test result ranged from 38.3% in
Michigan to 80.5% in Massachusetts.
 61.0% of cases had a positive hepatitis C RNA test result reported. The proportion with a
positive hepatitis C RNA test result ranged from 22.7% in Michigan to 88.0% in
Philadelphia.
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Table 4.5. Number and rate of hepatitis C-related deaths, by demographic characteristics 
and year – United States, 2009-2013 
Demographic 
characteristic 
2009 2010 2011 2012 2013 
No. Rate No. Rate No. Rate No. Rate No. Rate 
Age Group 
(years)§ 
0–34 116 0.08 117 0.08 128 0.09 158 0.11 121 0.08 
35–44 828 1.99 712 1.73 696 1.71 622 1.54 573 1.42 
45–54 5,469 12.26 5,171 11.49 5,073 11.34 4,749 10.73 4,344 9.93 
55–64 6,683 19.21 7,431 20.37 8,330 21.89 9,235 23.93 9,899 25.18 
65–74 1,824 8.77 1,901 8.75 2,136 9.50 2,515 10.49 3,004 11.91 
>75 1,333 7.10 1,293 6.97 1,357 7.18 1,369 7.15 1,425 7.31 
Race¶ 
White 12,682 4.43 









10575 4.03 11,196 4.19 11839 4.35 12219 4.40 
Black, NH 2981 7.72 3,167 7.89 3232 7.81 3520 8.35 
Hispanic 2318 6.83 2,555 7.15 2668 7.19 2699 6.91 
Asian/Pacific 
Islander 




248 9.90 275 10.61 313 11.81 324 12.22 
Sex 
Male 11,517 6.91 11,781 6.81 12,651 7.11 13,300 7.31 13,745 7.40 
Female 4,736 2.65 4,846 2.63 5,070 2.70 5,350 2.77 5,623 2.85 
Overall 16,253 4.70 16,627 4.65 17,721 4.82 18,650 4.96 19,368 5.03 
*Rates for race, sex, and overall total are age-adjusted per 100,000 U.S. standard population in 2000.
†Cause of death is defined as the underlying cause of death or one of the multiple causes of death and is based on
the International Classification of Diseases, 10th Revision (ICD-10) codes B17.1, and B18.2 (hepatitis C).
§Two deaths in 2010, one death in 2011, two deaths in 2012, and two deaths in 2013 are not represented under the
age category due to missing age data.
¶The race category "White" Included white, non-Hispanic and white Hispanic. The race category "Black" included
black, non-Hispanic and black Hispanic. The race category "Non-White, non-Black" included all other races.
**The race/ethnicity category was added starting in 2010 to incorporate bridged race categories. 65 deaths in 2010,
73 deaths in 2011, 126 deaths in 2012, and 111 deaths in 2013 are not represented under the race/ethnicity category
due to missing race and/or ethnicity data.
Source: CDC, National Vital Statistics System.
 Of the three types of viral hepatitis (hepatitis A, B, and C), hepatitis C accounted for the
greatest number of deaths and the highest mortality rate of 5.0 deaths/100,000 population
in 2013.
 The overall hepatitis C-related mortality rate increased from 4.7 deaths/100,000
population in 2009 to 5.0 deaths/100,000 population in 2013.
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 From 2009-2013, the age group with the highest hepatitis C-related mortality rate was 
persons aged 55-64 years (25.2 deaths/100,000 population in 2013). This group 
accounted for 51.1% of hepatitis C-related deaths in 2013. 
 In 2013, the racial/ethnic group with the highest hepatitis C-related mortality rate was 
among American Indians/Alaska Natives (12.2 deaths/100,000 population).  
 From 2009-2013, the hepatitis C-related mortality rate among American Indians/Alaska 
Natives increased by 23.2%.  
 In 2013, the hepatitis C-related mortality rate for males was approximately 2.6 times the 
rate for females. 
  




National surveillance data for acute viral hepatitis provide essential information for identifying 
patterns and trends in viral hepatitis; providing data for national and local estimates of the health 
burden of hepatitis A, B, and C; targeting groups for whom public health intervention is needed; 
and evaluating intervention efforts. National rates for acute hepatitis A and B have been 
published since 1966, and national rates for acute hepatitis C (formerly non-A, non-B) have been 
published since 1992. Major changes in the epidemiology of these diseases have occurred since 
reporting of these infections was initiated, largely resulting from implementation of prevention 
strategies, including the introduction of effective vaccines against hepatitis A and hepatitis B. 
NNDSS, the core of viral hepatitis surveillance, was designed to enable states to notify CDC of 
infectious diseases diagnosed with a single positive laboratory test. Cases of acute and chronic 
hepatitis B and C do not fit this pattern, as additional information beyond a single laboratory test 
is required to confirm a case (34). To better count and characterize cases of viral hepatitis and 
estimate the burden of disease, CDC supplements NNDSS data with data obtained from select 
funded sites, national surveys, and vital statistics. 
Data from NNDSS reveal an increase of: 27.4% in the number of reported cases of hepatitis A 
from 2011-2013, 5.4% in the number of reported cases of acute hepatitis B from 2012-2013, and 
151.5% in the number of reported cases of acute hepatitis C from 2010-2013. These increases are 
likely explained by the increases in foodborne outbreaks associated with hepatitis A and drug-
related and healthcare-related outbreaks associated with acute hepatitis B and C. In 2013, after 
adjusting for under-ascertainment and under-reporting, the estimated number of cases of HAV, 
HBV, and HCV infections was 3,473, 19,764, and 29,718, respectively. As noted in 
“Adjustments to Reported Cases in NNDSS”, these estimates cannot be compared directly with 
estimates from years prior to 2011, which were based on different methods of calculation. 
In addition to the recent increases in reported cases of acute hepatitis A, B, and C, chronic 
hepatitis infection continues to affect millions of Americans (7, 32). In 2013, over 30,000 reports 
of chronic hepatitis B and over 132,000 reports of chronic hepatitis C were submitted to CDC 
through NNDSS. Of these, 16,044 reports of chronic hepatitis B infection and 79,542 reports of 
chronic hepatitis C infections were available for descriptive analyses. Mortality data from 2013 
presented in this surveillance report show certain socio-demographic groups to be 
disproportionately dying with these infections, specifically, persons aged >55 years for hepatitis 
A; Asians/Pacific Islanders and persons aged 55-64 years for hepatitis B; and persons aged 55-64 
years for hepatitis C. Mortality rates in 2013 were highest among persons infected with HCV 
(5.03 deaths per 100,000 population) and increased from the previous year, followed by HBV 
(0.52 deaths per 100,000 population), and HAV (0.02 deaths per 100,000 population). 
CDC and state health departments rely on surveillance data to track the incidence of acute 
infection, guide development and evaluation of programs and policies designed to prevent 
infection and minimize the public health impact of viral hepatitis, and monitor progress towards 
achieving goals established for these programs and policies. Effective systems for conducting 
surveillance for chronic HBV and HCV infections are needed to ensure accurate reporting of all 
cases and to support and evaluate prevention activities. Additional investments in surveillance at 
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the local, state, and national levels are essential to build strong prevention programs that interrupt 
transmission of viral hepatitis and improve the health of those who are currently infected.  
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